Heska (HSKA) Return on Equity ROE from the first quarter 2023 to first quarter 2022 and annually, average high and low, overall ranking from Mar 31 2023 to Mar 31 2022 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Heska Corporation  (NASDAQ: HSKA)

Heska's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Heska in the first quarter 2023?
Heska Corporation recorded a cumulative net loss of $-20 million during 12 months ending in the first quarter 2023, resulting in a negative return on equity (ROE) of -4.81%.

Within the In Vitro & In Vivo Diagnostic Substances industry 3 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 2638, from total ROE ranking in the fourth quarter 2022 at 3082.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter		 (Mar 31 2022)
I. Quarter
Y / Y Equity Change -2.55 % -3.13 % -6.2 % -3.8 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -20 -20 -26 -27 -24
Return On Equity (TTM) -4.81 % -4.75 % -6.07 % -6.32 % -5.49 %
HSKA's Total Ranking # 2638 # 3082 # 2676 # 2855 # 2897
Equity (TTM) in Millions 418 422 408 417 429
Seq. Equity Change -1.07 % 3.51 % -2.25 % -2.64 % -1.67 %
Seq. Net Income Change - - - - -

Back to HSKA Management Effectiveness >> HSKA's 5 Years Annual ROE >> Compare HSKA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 4
Sector # 204
Overall # 2638

Return On Equity Statistics
High Average Low
17.93 %
2.88 %
-7.74 %
(Mar 31 2017)   (Sep 30 2020)





HSKA Annual Return On Equity (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018
Total Equity in Millions 422 436 287 154 122
Y / Y Equity Change -3.13 % 51.84 % 85.96 % 26.11 % 21.87 %
Net Income in Millions -20 -1 -15 -2 6
Y / Y Net Income Change - - - - -38.13 %
Return On Equity -4.71 % -0.26 % -5.14 % -1.12 % 4.78 %

Back to HSKA Management Effectiveness >> HSKA's 5 Years Annual ROE >> Compare HSKA ROE to its Competitors




More Return On Equity Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
HSKA's' Return on Equity at Yahoo Finance
HSKA's Roe Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for HSKA's Competitors
Subscribers only: Roe for Heska's Suppliers
Subscribers only: Return On Equity for HSKA's Customers




Companies with similar Return On Equity at Mar 31 2023, within Healthcare Sector ROE

Date modified: 2026-09-12T06:18:48+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.